Sensorcaine-MPF (Bupivacaine HCl and Epinephrine Injection, USP) with Epinephrine 1:200,000 (as b...

FDA Recall #D-0129-2023 — Class II — November 22, 2022

Recall #D-0129-2023 Date: November 22, 2022 Classification: Class II Status: Terminated

Product Description

Sensorcaine-MPF (Bupivacaine HCl and Epinephrine Injection, USP) with Epinephrine 1:200,000 (as bitartrate), 0.25%, 25 mg per 10 mL (2.5 mg per mL), 10 mL Single Dose Vial (NDC 63323-468-01), packaged in 25 Single Dose Vials per tray (NDC 63323-468-17), Rx only, Fresenius Kabi, Lake Zurich, IL 60047.

Reason for Recall

Subpotent Drug: Testing results below the defined limit for the epinephrine portion of this product.

Recalling Firm

Fresenius Kabi USA, LLC — Lake Zurich, IL

Classification

Class II — May cause temporary or medically reversible adverse health consequences.

Product Type

Drugs

Product Quantity

31,600 vials

Distribution

Nationwide in the USA

Code Information

Batch #: 6128800, exp 12/2023

Status

Terminated

Voluntary / Mandated

Voluntary: Firm initiated